Important Information for Walgreens Boots Alliance, Inc. (WBA) Stockholders: Deadline Reminder for Securities Class Action Lawsuit
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Walgreens Boots Alliance, Inc. (WBA) between April 2, 2020, and January 16, 2025 (the “Class Period”), of the significant March 31, 2025 lead plaintiff deadline. If you purchased Walgreens common stock during this timeframe, you may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement.
Background
Walgreens Boots Alliance, Inc. is a global leader in retail and wholesale pharmacy. The company operates through its subsidiaries, Walgreens and Duane Reade, which together form the largest retail pharmacy chain in the United States. Walgreens provides a wide range of products and services, including prescription and non-prescription drugs, health and wellness services, and retail goods. In addition, the company operates a pharmacy benefit manager, Walgreens Pharmacy Services, and a wholesale business, Alliance Healthcare.
Class Action Lawsuit
The lawsuit alleges that Walgreens and certain of its executives made false and misleading statements regarding the company’s business, operational, and financial metrics, including revenues, earnings, and pharmacy sales growth. Specifically, the complaint alleges that defendants failed to disclose that: (1) the company was experiencing declining retail sales and customer traffic, (2) the company’s pharmacy sales growth was being driven by increased dispensing of generic drugs, and (3) the company’s cost savings initiatives were not progressing as planned.
Impact on Individual Investors
If the allegations in the lawsuit are proven true, investors who purchased Walgreens common stock during the Class Period may have suffered significant losses. The lawsuit seeks to recover damages for these investors, who may be eligible to join the class action as plaintiffs and share in any potential recovery. The lead plaintiff deadline, which is rapidly approaching, is crucial for investors to act if they wish to participate in the case.
Impact on the World
The consequences of this lawsuit could extend beyond the affected investors. The alleged misrepresentations could potentially impact the public’s trust in Walgreens and the pharmacy industry as a whole. Furthermore, the outcome of the lawsuit could set a precedent for future securities class actions, potentially encouraging more investors to come forward with similar claims against publicly traded companies.
Conclusion
If you purchased Walgreens common stock between April 2, 2020, and January 16, 2025, and wish to learn more about the class action lawsuit or join the case as a lead plaintiff, please contact Rosen Law Firm by calling (212) 614-5441 or sending an email to [[email protected]](mailto:[email protected]) or filling out the form on the firm’s website at www.rosenlegal.com/cases-register-2252.html. The firm represents investors worldwide, and consultation with the firm does not result in any financial obligation or requirement to participate in the litigation.
Rosen Law Firm is dedicated to ensuring that corporations are held accountable for misleading their investors. The firm’s expertise and experience in securities litigation makes it a powerful ally for investors in recovering losses resulting from securities fraud.
With the lead plaintiff deadline fast approaching, it is essential for investors to act promptly if they wish to participate in the case. Contact Rosen Law Firm today to learn more about your options and protect your investment.
Disclaimer: This press release may be considered attorney advertising. In some jurisdictions, it may be considered a solicitation for business. Rosen Law Firm has not yet taken and will not take any action to process this press release as a ‘paid-for’ advertising. Rosen Law Firm is an active member of The National Association of Securities Professionals.
